Out on 21 March 2019

Bad Blood

John Carreyrou

4.44 based on 1 ratings & 0 reviews on Goodreads.com

2018 Nominee

Financial Times and McKinsey Business Book of the Year

See more book details
21 March 2019
9781509868087
320 pages
Synopsis

A New York Times bestseller.
Winner of the Financial Times/McKinsey Business Book of the Year Award.

'Chilling . . . Reads like a West Coast version of All the President’s Men.' New York Times Book Review

The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.

In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.

In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Now to be adapted into a film, with Jennifer Lawrence to star.

A dazzling story of deception in Silicon Valley . . . It is a tale of heroic cupidity on a scale that made the very best and the very brightest look like the very, very foolish . . . You will not be able to put this book down.

Washington Post

Riveting . . . a blistering critique of Silicon Valley, a kind of nonfiction corollary to Dave Eggers's The Circle . . . compelling . . . [Carreyrou's] unmasking of Theranos is a tale of David and Goliath . . . The real heroes, though, are his sources: the young scientists who worked at the company and risked their reputations and careers by voicing their concerns. Were it not for their courage, Theranos might still be testing blood today

David Crow - Financial Times